StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies on Amgen (AMGN): Elegrobart data not a 'significant competitive threat to Tepezza'
March 30, 2026 4:38 PM
Jefferies analyst Akash Tewari reiterated a Hold rating and $350.00 price target on Amgen (NASDAQ: AMGN)The analyst commented, "We got ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
